ライフサイエンスコーパス: vaccine development

1 antigens, which could be exploited in future vaccine development.

2 ng antibodies (bNAbs) is a major goal of HIV vaccine development.

3 animal papillomavirus models for therapeutic vaccine development.

4 d that phage proteins may be a candidate for vaccine development.

5 s (bnAbs) has been a major obstacle to HIV-1 vaccine development.

6 ease control, notification of outbreaks, and vaccine development.

7 ralizing epitope, which can be exploited for vaccine development.

8 antibodies (bnAbs) is a primary goal of HIV vaccine development.

9 SIV-specific TFH cells would greatly benefit vaccine development.

10 erial adhesin A), both of which were used in vaccine development.

11 ve not been identified, creating hurdles for vaccine development.

12 the RSV fusion (F) protein, a key target in vaccine development.

13 s of such features is essential for rational vaccine development.

14 tective immune responses, continue to hinder vaccine development.

15 ently focus on the promising pipeline of RSV vaccine development.

16 ave important implication for antiretroviral vaccine development.

17 ay pave the way for future express antiviral vaccine development.

18 ZIKV CHIM could de-risk and accelerate ZIKV vaccine development.

19 n by T cells from immune women could advance vaccine development.

20 infections provide support for investment in vaccine development.

21 pport further studies with Ad5/3 for malaria vaccine development.

22 helps fill the gap in clinical tuberculosis vaccine development.

23 monoclonal antibodies, which may inform HCV vaccine development.

24 selective pressure, restricting their use in vaccine development.

25 antibodies, has become the focus for subunit vaccine development.

26 understanding cellular immunity for targeted vaccine development.

27 resentative HCV genome, which may inform HCV vaccine development.

28 arsenal of multivalent immunogens for HIV-1 vaccine development.

29 ailed experimental medicine studies early in vaccine development.

30 r, continues to present thorny challenges to vaccine development.

31 onal design of glycopeptide antigens for HIV vaccine development.

32 and to consider the prospects for norovirus vaccine development.

33 Thus, V1V2 is a key target for vaccine development.

34 nistering membrane-bound proteins for future vaccine development.

35 galovirus (CMV) transmission has complicated vaccine development.

36 ed to address these knowledge gaps and guide vaccine development.

37 provides a mechanism for attenuating RSV for vaccine development.

38 y in humans, will be required for successful vaccine development.

39 tate-of-art technologies greatly accelerated vaccine development.

40 andemic preparedness strategies include H7N9 vaccine development.

41 D4 binding site (CD4bs), is a major focus of vaccine development.

42 41 region is a key and safe target for HIV-1 vaccine development.

43 this unique non-human primate model for HIV vaccine development.

44 eaved to (gp120/gp41)3] poses challenges for vaccine development.

45 CV pathogenesis, lentivirus coinfection, and vaccine development.

46 of HIV-1 control that may be relevant to HIV vaccine development.

47 s an ideal target for novel therapeutics and vaccine development.

48 t remains neglected as a priority of malaria vaccine development.

49 e bacterium and is a prime target in current vaccine development.

50 rrelate may be a key target for dengue virus vaccine development.

51 Ps and labile thiolactone bond have hindered vaccine development.

52 it has the potential to be used for drug and vaccine development.

53 nctional HIV-1 Env; they can guide effective vaccine development.

54 neutralizing mAbs are an important guide for vaccine development.

55 uld be targeted for rational structure-based vaccine development.

56 s to help overcome the barriers to effective vaccine development.

57 data for understanding RSV transmission and vaccine development.

58 s mediating protection is a major barrier to vaccine development.

59 hese 5 Ebolavirus species, which complicates vaccine development.

60 alization patterns have implications for HCV vaccine development.

61 hts the need for effective approaches to CoV vaccine development.

62 ted in vaccine trials is critical to advance vaccine development.

63 mount a response to HSV will be important to vaccine development.

64 n advance in seasonal and pandemic influenza vaccine development.

65 trategy as a promising approach for MERS-CoV vaccine development.

66 has implications for antigenic diversity and vaccine development.

67 g the need for empirical epitope testing for vaccine development.

68 e of specific epitopes is critical for HIV-1 vaccine development.

69 mechanistic insights vital for anti-helminth vaccine development.

70 r viral control with potential relevance for vaccine development.

71 its, is the focus of multiple strategies for vaccine development.

72 piratory tract and bear upon live attenuated vaccine development.

73 o facilitate structure-based drug design and vaccine development.

74 tential clinical use of M8 as an adjuvant in vaccine development.

75 rsistence and presenting a challenge for HCV vaccine development.

76 istic differences could be important for HCV vaccine development.

77 , and their structural utility in new cancer vaccine development.

78 ctors with cGAMP therefore holds promise for vaccine development.

79 Application and utility of mass cytometry in vaccine development.

80 n vaccine efficacy that can influence future vaccine development.

81 inform new strategies for virus control and vaccine development.

82 nction may provide insights relevant to ETEC vaccine development.

83 ffirms the complex as a candidate target for vaccine development.

84 cy in both types of responses and constrains vaccine development.

85 synthesis of an important decasaccharide for vaccine development.

86 tood, which poses a major barrier to malaria vaccine development.

87 that this protein is an excellent target for vaccine development.

88 tions appears discordant with strategies for vaccine development.

89 ins difficult, and hindering M protein-based vaccine development.

90 tant implications in tumor immunotherapy and vaccine development.

91 of antibody sequence data in the context of vaccine development.

92 ion with B cells, and which hold promise for vaccine development.

93 ced understanding of typhoid and was used in vaccine development.

94 outcome of infection is a concern for dengue vaccine development.

95 e represents a crucial subunit candidate for vaccine development.

96 rn rat brains and may be good candidates for vaccine development.

97 ations for anticytokine biologic therapy and vaccine development.

98 nal studies of viral intrahost variation and vaccine development.

99 of natural immunity and hindering effective vaccine development.

100 genotypes should be the focus of future DENV vaccine development.

101 coprotein (Env) trimer represent barriers to vaccine development.

102 sis and developing diagnostic assays and for vaccine development.

103 rescue of host natural humoral immunity and vaccine development.

104 s unique polysaccharide has implications for vaccine development.

105 EMS Shigella serotypes are reviewed to guide vaccine development.

106 odies (bNAbs) is an important goal for HIV-1 vaccine development.

107 says typically used in support of flavivirus vaccine development.

108 been recently made in basic RSV research and vaccine development.

109 its six Duffy binding-like (DBL) domains for vaccine development.

110 se binding sites important targets for HIV-1 vaccine development.

111 ive antigens experimentally proven valid for vaccine development.

112 (F) subunit vaccine candidates have hampered vaccine development.

113 gest new approaches for structure-aided MPER vaccine development.

114 -HIV 2F5 antibody, a research focus in HIV-1 vaccine development.

115 s will need to be considered in future HIV-1 vaccine development.

116 dy-mediated mucosal immunity while informing vaccine development.

117 en the major focus of research in individual vaccine development.

118 aracterization of NAb interactions can guide vaccine development.

119 optimal candidates for diagnostic assays and vaccine development.

120 ication provide a useful model to inform HIV vaccine development.

121 he primary neutralizing antigen critical for vaccine development.

122 l diseases with a focus on new paradigms for vaccine development.

123 d identify suitable targets for antiviral or vaccine development.

124 enesis and is therefore a primary target for vaccine development.

125 ate the global pace of clinical tuberculosis vaccine development.

126 support efforts to target these proteins for vaccine development.

127 has proven to be a significant challenge for vaccine development.

128 nd their genetic diversity may influence GBS vaccine development.

129 ed congenital infections have prompted rapid vaccine development.

130 ns of pathogenesis, virulence regulation and vaccine development.

131 odies (bNAbs) against HCV is a major goal of vaccine development.

132 isms have been the major focus in individual vaccine development.

133 view of progress in the field of Ebola virus vaccine development.

134 antigenicity, which is critical to influenza vaccine development.

135 provide valuable insights into antiviral and vaccine development.

136 h applications in flavivirus diagnostics and vaccine development.

137 ) differentiation in malaria is critical for vaccine development.

138 veillance and control measures and informing vaccine development.

139 Thus, they are attractive immunogens for vaccine development.

140 l/79906/2009 (H10N7) as a suitable virus for vaccine development.

141 thogenesis, immune control, and prophylactic vaccine development.

142 uring infection, making it a good target for vaccine development.

143 tion of functional antibodies, necessary for vaccine development.

144 immunogens with the potential to advance HIV vaccine development.

145 c variation in H pylori poses a challenge to vaccine development.

146 zing antibodies (bNAbs) are a focus of HIV-1 vaccine development.

147 Here we review the current state of ZIKV vaccine development.

148 ent field forward and directed new candidate vaccine development.

149 or rational structure-based, next-generation vaccine development.

150 cross the globe, and the challenges posed to vaccine development.

151 nt for understanding the potential for HSV-2 vaccine development.

152 se them to develop novel glycoconjugates for vaccine development.

153 nding virus-host interactions is crucial for vaccine development.

154 s to establish protection efficiency for new vaccine developments.

155 SV)-associated morbidity and mortality makes vaccine development a priority.

156 Vaccine development against CHIKV has proved challenging

157 e platform may be a valuable tool for timely vaccine development against emerging infectious diseases

158 n system, has broad applicability for use in vaccine development against encapsulated microbial patho

159 Our findings can also be applied to vaccine development against other flaviviruses, such as

160 mplex class I epitopes is a crucial step for vaccine development against T. cruzi.

161 ic diversity has posed a critical barrier to vaccine development against the pathogenic blood-stage i

162 cific CD8(+) T cells that will inform future vaccine development against this and other pathogens.

163 idemic in West Africa increased the focus on vaccine development against this hemorrhagic fever-causi

164 al major pathogens have resisted traditional vaccine development, although vulnerable epitopes target

165 lied areas, e.g. as antiviral drugs, for the vaccine development and as novel biosensors, such glycom

166 vation could have important ramifications in vaccine development and clinical care.

167 volution within pigs as well as for improved vaccine development and control strategies in swine.

168 our understanding of RSV immunity and inform vaccine development and delivery strategies for all sett

169 esearch, policy, and resource allocation for vaccine development and delivery.

170 ictive cellular immune correlate could guide vaccine development and evaluation.

171 ue to identify protective profile useful for vaccine development and for pathogenesis studies.

172 This approach has rejuvenated the field of vaccine development and has fostered hope that new ways

173 n of an insect-specific virus in preclinical vaccine development and highlights the potential applica

174 Despite progress in vaccine development and immunization delivery systems wo

175 o overcome significant challenges related to vaccine development and immunotherapy.

176 nanocarriers with potential applications in vaccine development and immunotherapy.

177 in this area have important implications in vaccine development and new treatment paradigms against

178 on ZIKV and proposes critical questions for vaccine development and other areas of needed research.

179 results have important implications for ZIKV vaccine development and provide a mouse model for evalua

180 es that must be overcome in order to advance vaccine development and provide reagents for HIV researc

181 responsible for pathogen protection enables vaccine development and provides insights into host defe

182 standing adaptive immunity should facilitate vaccine development and reduce the global effect of resp

183 inform future developments in staphylococcal vaccine development and studies into the requirements fo

184 cosal tissue may prove critical to effective vaccine development and the prophylactic use of monoclon

185 PV research community in HPV serological and vaccine development and to define mechanisms of HPV upta

186 is could represent an obstacle for universal vaccine development and warrants further investigation.

187 fore have implications for autoimmunity, for vaccine development, and for understanding long-term pat

188 enic mosquito-borne alphaviruses, facilitate vaccine development, and inform potential strategies to

189 mmunodeficiency virus pathogenesis, drug and vaccine development, and the potential for clinical tran

190 e implications for future virology research, vaccine development, and virology as a whole.

191 community to explore ZIKV molecular biology, vaccine development, antiviral development, diagnostics,

192 A 'One Health' vaccine development approach, in which the same vaccine

193 emic, coupled to challenges with traditional vaccine development approaches, point toward a need for

194 ce a functional recombinant MOMP protein for vaccine development are limited by poor solubility, low

195 troviral therapy, diagnostic approaches, and vaccine development are providing novel tools for treatm

196 Alternate approaches for vaccine development are urgently needed.

197 lation should be further investigated in HIV vaccine development as a novel correlate of immunity.

198 protective immune responses are essential to vaccine development as they can provide selection criter

199 promises a new heyday for drug discovery and vaccine development as well as the basic biology of thes

200 ecoration of nanoparticles should accelerate vaccine development, as well as other applications of na

201 s is, to our knowledge, the first successful vaccine development based on gene edit technologies, dem

202 s for studies of dengue pathogenesis and for vaccine development, because enhancement, not just lack

203 Initial attempts at CHIKV vaccine development began in the early 1960s.

204 ity, posing a desperate demand for efficient vaccine development biotechnologies.

205 published mass cytometry studies relevant to vaccine development, briefly compare immune profiling by

206 lizing antibodies (bnAbs) is a goal of HIV-1 vaccine development but has remained challenging partial

207 e data has the potential to advance rational vaccine development but yet there are no licensed vaccin

208 ts and therefore serve as a useful guide for vaccine development, but our understanding of resistance

209 ibodies and potential candidates for subunit vaccine development, but our understanding of their neut

210 LT antigens are often used in vaccine development, but STa has not been included becau

211 cal practice could streamline and accelerate vaccine development by offering a time- and resource-eff

212 Malaria vaccine development continues to be hindered by a poor u

213 The rapid progress in vaccine development demonstrates the capacity of governm

214 se genomes will facilitate research aimed at vaccine development, diagnosis, and the evaluation of cl

215 uction is applicable to other flavivirus VLP vaccine development, due to the similarity in viral stru

216 Dengue vaccine development efforts are challenged by immunologi

217 ave been identified, and a number of current vaccine development efforts are focused on generating ea

218 Vaccine development efforts have recently focused on ena

219 Current vaccine development efforts largely target Plasmodium fa

220 vide a stronger basis for drug discovery and vaccine development efforts.

221 ies are difficult to elicit and inform HIV-1 vaccine development efforts.

222 STLV-infected baboons as a model system for vaccine development efforts.

223 d Guillain-Barre syndrome led to accelerated vaccine development efforts.

224 ry, we describe key hurdles facing the HIV-1 vaccine development field and outline strategies to acce

225 cal HIV-1 vaccine trials has moved the HIV-1 vaccine development field forward and directed new candi

226 ng pathogens represents an important goal in vaccine development for a wide variety of pathogens.

227 efficacy, has the potential to revolutionize vaccine development for respiratory infections.

228 D (gD-2) have been the major focus of HSV-2 vaccine development for the past 2 decades.

229 in pathogenesis and highlight an approach to vaccine development for this infectious cancer.

230 HBoV1 mutants may have particular utility in vaccine development for this virus.

231 However, vaccine development has been confounded because of HCV's

232 Malaria vaccine development has been dominated by the subunit ap

233 However, HIV vaccine development has been hampered by significant sci

234 Vaccine development has been hampered by the lack of hig

235 However, vaccine development has been impeded by a paucity of imm

236 Vaccine development has been problematic in part due to

237 A major obstacle for vaccine development has been the traditional understandi

238 Effective vaccine development has been unsuccessful, but surveilla

239 EBV vaccine development has focused on the major membrane gl

240 Vaccine development has had a huge impact on human healt

241 Vaccine development has largely focused on the ability o

242 For some viruses vaccine development has not been successful after multip

243 Human respiratory syncytial virus (hRSV) vaccine development has received new impetus from struct

244 Influenza vaccine development has traditionally focused on produci

245 The advances in subunit vaccines development have intensified the search for pot

246 creased density of Env are being pursued for vaccine development; however, these typically require pr

247 These data have implications for vaccine development in describing a target time point to

248 us, for several important studies, including vaccine development, in vitro systems enabling high-tite

249 Significant hurdles to vaccine development include host range specificity, maki

250 Traditionally, vaccine development involves tradeoffs between immunogen

251 A major goal for HIV-1 vaccine development is an ability to elicit strong and d

252 An important step toward vaccine development is defining protective immune respon

253 Cryptosporidiosis drug and vaccine development is limited by the poor tractability

254 A major challenge in dengue vaccine development is that cross-reactive anti-DENV Abs

255 One of the goals of HIV-1 vaccine development is the elicitation of neutralizing a

256 A persistent goal of vaccine development is the enhancement of the immunogeni

257 A major goal for HIV-1 vaccine development is the production of an immunogen to

258 A strategy for HIV-1 vaccine development is to define envelope (Env) evolutio

259 A goal of HIV-1 vaccine development is to elicit broadly neutralizing Ab

260 A central effort in HIV vaccine development is to generate protective broadly ne

261 A challenge for HCV vaccine development is to identify conserved epitopes ab

262 One goal of HIV-1 vaccine development is to induce antibodies that are sim

263 HCV vaccine development is vital in the effort toward diseas

264 n strategies used in therapeutic antibody or vaccine development, it is critical to assess the qualit

265 amine two realistic new aspects pertinent to vaccine development: loss in B cell diversity across suc

266 and therefore could be a target for drug or vaccine development.Many strains of Plasmodium differ in

267 berculosis (TB) disease elimination by 2050, vaccine development needs to occur now.

268 oof of principle that can inform prospective vaccine development not only for gonorrhoea but also for

269 s, others have failed safety trials, placing vaccine development on a hit-or-miss trajectory.

270 Plasmodium falciparum transmission-blocking vaccine development, Pfs25, is a sexual stage surface pr

271 of PsA-TT highlighted the value of a robust vaccine development plan and design so that lessons lear

272 stinfection and postvaccination, although no vaccine-development program has yet systematically emplo

273 Based on prior flavivirus vaccine development programs, knowledge of flavivirus pa

274 human immunodeficiency virus type 1 (HIV-1) vaccine development programs.

275 r deploying mass cytometry in the context of vaccine development.-Reeves, P.

276 y durability, is the major challenge for HIV vaccine development, regardless of the immunogen or vacc

277 Vaccine development requires production, in quantities s

278 Thus, vaccine development should focus on designing regimens t

279 ects on chronic pathology, natural immunity, vaccine development strategies, immune disorders, and dr

280 in humans is critical for tuberculosis (TB) vaccine development strategies.

281 gned centralized immunogens for global HIV-1 vaccine development strategies.

282 Here we present an express vaccine development strategy based on CRISPR/Cas9 and Cr

283 tribute to a pool of peptides identified for vaccine development that can be tested in vitro to confi

284 human immunodeficiency virus type 1 (HIV-1) vaccine development that is complicated by variations in

285 ce of conserved neutralizing epitopes in HCV vaccine development that map to antigenic clusters in E2

286 the 21st century, molecular biology permits vaccine development that was not possible before.

287 of of principle to support as a strategy for vaccine development the discovery and manipulation of FP

288 several impeding factors have limited Ebola vaccine development, the current epidemic has provided a

289 rotection that will assist respiratory virus vaccine development, these studies extend the developmen

290 rotein spike (Env) of HIV-1 is the target of vaccine development to elicit broadly neutralizing antib

291 sporadic pandemic outbreaks requires further vaccine development to induce cross-protective humoral r

292 Although vaccine development to modify this congenital infection

293 To overcome the current impasse in vaccine development, we need to define the phenotype of

294 ons are intended to help stimulate continued vaccine development while ensuring appropriate assessmen

295 an mediate heterosubtypic responses, typical vaccine development will augment either humoral or cellu

296 The next steps for malaria vaccine development will focus on the design of a produc

297 Antiviral and vaccine development would benefit from a detailed mechan

298 D4 binding site (CD4bs), is a major focus of vaccine development yet to be accomplished.

299 pathogenesis and would benefit antiviral and vaccine development, yet the presence of more than a doz

300 have been tested preclinically for pulmonary vaccine development, yet the role of NP surface charge o